Oakland, CA, United States
Oakland, CA, United States

Time filter

Source Type

News Article | May 2, 2017
Site: www.prlog.org

Dustin Muriel, the aspiring hip hop singer has been releasing back to back new beats in soundcloud. Log onto soundcloud and listen to his new single "Actavis".


MADISON, Wis., April 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed John Friend, II, M.D. as vice president and chief medical officer effective April 17, 2017. “Cellectar has accelerated and expanded its research and development program to include multiple clinical trials for our lead product candidate CLR 131, as well as the active preclinical development of additional compounds utilizing our PDC platform,” said Jim Caruso, president and CEO of Cellectar Biosciences. “John’s depth of drug development experience in the biopharmaceutical industry, specifically, advancing drugs from preclinical stage through clinical studies, as well as successful oversight of the regulatory process, precisely meets our current need in helming our PDC programs and we look forward to benefitting from his leadership.” Dr. Friend, age 47, brings 15 years of global drug development expertise and general management experience in oncology, inflammation, endocrine/metabolism, and pain management to Cellectar.  Prior to joining the company, John spent more than seven years at Helsinn Therapeutics leading its research and development division.  Most recently he served as senior vice president of Medical and Scientific Affairs at Helsinn, building the non-clinical, clinical, medical and regulatory affairs teams to lead multiple global franchises from early product development to market commercialization. Prior to his time at Helsinn, Dr. Friend held executive responsibility for clinical research, medical affairs, pharmacovigilance and risk management at various pharmaceutical companies including Akros Pharma, Actavis, Alpharma, Hospira and Abbott.  After obtaining an undergraduate degree in Chemistry from Southern Methodist University, John earned his medical degree from UMDNJ-Robert Wood Johnson Medical School (now Rutgers, RWJMS).  He completed post-graduate residency program in family medicine and subsequently served as clinical director and faculty attending physician at Cabarrus Family Medicine Residency Program in North Carolina.   About Cellectar Biosciences, Inc. Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer-targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma, as well as a Phase II clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1603-PTX), a preclinical-stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit www.cellectar.com. This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.


News Article | April 20, 2017
Site: www.prnewswire.com

Zubsolv® growth in the US drives improved profitability in the commercial operations In a dynamic market environment, I am pleased to report that net sales for Zubsolv US in Q1 2017 increased with 15.9 percent from Q1 2016 and our US business continues to contribute positively to the Orexo revenues and earnings. With this growth and positive contribution from our US business, I can confirm our financial guidance of positive EBITDA for the full year. We are encouraged to see an accelerating growth in the market for treatment of opioid dependence reaching 9.7 percent in the first quarter compared to a growth of 7.6 percent in Q4 2016. This is a trend break as Q1 traditionally is weaker than Q4. The growth this year is primarily driven by the physicians certified to expand to 275 patients and most of the growth is in the public segment. The commercial segment has followed the trend from previous years with Q1 slightly below Q4 volumes. We expect the commercial segment to improve in the next quarters and we are pleased to see the growth in commercial pick-up late in the quarter. This is important for Orexo as we have better market access, market share and pay less rebates in the commercial segment. During the quarter, I have spent time in the US meeting healthcare professionals treating opioid dependence. The feedback on Zubsolv and our work in the US is positive, we have a strong brand awareness both as a company and on a product level with Zubsolv. However, market access remains an important driver of physicians' choice of medication and we need to work relentlessly to open up the market for more unrestricted access for Zubsolv. I know our message resonates well, but physicians need to move out of their comfort zone and direct their patients to get a treatment with Zubsolv versus a "drug" most patients have tried before even starting medical treatment, since they were buying it on the street as a part of their illicit opioid misuse. Another key event during the quarter was a new litigation against Actavis for infringement of our patent 8,454,996 with their generic versions of Suboxone® and Subutex®. The validity of the '996 patent was confirmed by the district court and Actavis has not appealed the decision. Actavis has been successful with the generic version of Suboxone and was the market leader the first year after launch in March 2013. The total cumulated gross sales of the generic versions of Suboxone and Subutex exceed USD 500 million and Orexo will seek compensation for damages caused by Actavis's infringement of the '996 patent. I remain confident that we will continue to see a positive development of Zubsolv and Orexo, spurred by improved market and volume growth in the US. Beyond Zubsolv in the US, our pipeline is progressing well. Zubsolv launch in Europe is anticipated early next year, we have concrete discussions with partners for OX51 and OX-MPI and we have some exciting new formulation technologies which could be ready for first clinical trials already this year. With our continued strengthening of our financial position, with six consecutive quarters with positive cash flow from operating activities, we are well positioned to capture the opportunities and continue the development of Orexo. For further information, please contact : Nikolaj Sørensen, President and CEO, or Henrik Juuel, EVP and CFO Tel +46-18-780-88 -0  E-mail ir@orexo.com CEO Nikolaj Sørensen and CFO Henrik Juuel will present the report at a teleconference on April 20, 2017, at 2:00pm CET. Please view instructions below on how to participate. Internet: https://wonderland.videosync.fi/orexo-q1-report-2017. Telephone: (SE) +46 8 566 425 09, (UK) +44 20 300 89 807 or (US) +1 855 831 5945. There will be a Q&A session and questions can also be sent in advance to ir@orexo.com at latest 11am CET. The presentation will be available at Orexo´s website one hour prior to the teleconference. This information is information that Orexo AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00am CET on April 20, 2017. This information was brought to you by Cision http://news.cision.com http://news.cision.com/orexo/r/interim-report-q1-2017,c2242893 The following files are available for download: To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/orexo---interim-report-q1-2017-300442507.html


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2017" report to their offering. The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2017 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets. The report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets. The focus of the report is on partnerships for business, product, technology and royalty assets where partners have entered an agreement to dispose of or acquire said assets. Companies may seek to dispose of an asset simply because it is surplus to requirements. Or it may seek to dispose of assets in order to raise funds to invest in others parts of its business. Or it may be due to a regulatory requirement to dispose of certain business or product assets as a result of a pending business merger in order to meet competition regulations. The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others. The report focuses on four primary types of asset available for purchase: In Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2017, the available deals are listed by: For more information about this report visit http://www.researchandmarkets.com/research/g7x5ql/global_asset


LONDON, May 4, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/3812932/ Description The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2017 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets. The report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets. The focus of the report is on partnerships for business, product, technology and royalty assets where partners have entered an agreement to dispose of or acquire said assets. Companies may seek to dispose of an asset simply because it is surplus to requirements. Or it may seek to dispose of assets in order to raise funds to invest in others parts of its business. Or it may be due to a regulatory requirement to dispose of certain business or product assets as a result of a pending business merger in order to meet competition regulations. The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. The report focuses on four primary types of asset available for purchase: Business assets - the most common asset exchanging hands. Business assets are in the form of a business unit or subsidiary of a parent company. Common assets include territorial businesses or non-core businesses such as an OTC or diagnostics business, separate from the core business operations Product assets - in the form of marketed product, clinical phase development compound, or drug delivery-compound combination. These assets are commonly available as a result of a merger or change in direction of the selling company. The buyer acquires the asset for global or territorial exploitation. It is often the case that the acquiring company is normally a competitor to the seller, but in this situation the trade is of mutual benefit Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product Technology asset - where a buyer is acquiring a technology platform, research program, patent portfolio or other intellectual property asset. The acquisition is often due to the technology being surplus to a sellers interests, but may also be as a consequence of a sale of assets in advance of the seller entering liquidation Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of over 1,000 asset purchase deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of Asset Purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in Asset Purchase as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of Asset Purchase deals. The chapter includes numerous case studies to enable understanding of both pure Asset Purchase deals and multicomponent deals where Asset Purchase forms a part. Chapter 4 provides a review of the leading Asset Purchase deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a comprehensive listing of the top 50 most active Asset Purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. Chapter 6 provides a comprehensive and detailed review of Asset Purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2010 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Asset Purchase deal. The appendices to the report includes a comprehensive listing of all Asset Purchase deals announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document. The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others. The report also includes numerous table and figures that illustrate the trends and activities in Asset Purchase dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about Asset Purchase alliances. Key benefits Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2017 provides the reader with the following key benefits: - In-depth understanding of asset purchase deal trends since 2010 - Analysis of the structure of asset purchase agreements with numerous real life case studies - Comprehensive access to over 1,000 actual asset purchase deals entered into by the world's biopharma companies - Detailed access to actual asset purchase deals entered into by leading biopharma companies - Insight into the terms included in a asset purchase agreement, together with real world clause examples - Understand the key deal terms companies have agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2017 is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide. Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2017 includes: - Trends in asset purchase dealmaking in the biopharma industry since 2010 - Analysis of asset purchase deal structure - Case studies of real-life asset purchase deals - Access to over 1,000 asset purchase deal records - The leading asset purchase deals by value since 2010 - Most active asset purchase dealmakers since 2010 - The leading asset purchase partnering resources In Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2017, the available deals are listed by: - Company A-Z - Headline value - ge of development at signing - Therapeutic area - Technology type Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available. The Global Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive access to available records for over 1,000 asset purchase deals, including contract documents where available. Analyzing actual contract agreements allows assessment of the following: - What are the precise rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How aresalesand payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - How is confidentiality and publication managed? - How are disputes to be resolved? - Under what conditions can the deal be terminated? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law? Download the full report: https://www.reportbuyer.com/product/3812932/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com   For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com   Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-asset-purchase-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2010-to-2016-300451761.html


LONDON, May 4, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/4882433/ Description The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010- 2017 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest licensing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of licensing agreements from 2010 to 2017. There has been a long standing willingness for parties to enter licensing deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages. Licensing is a specific type of partnering deal whereby the parties to the deal agree to commercialize a compound, product or technology. Specifically, licensing is the granting of permission to use intellectual property rights, such as trademarks, patents, or technology, under defined conditions There are several forms of licensing deal. Traditional licensing arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subsequent sales of product(s) derived from the intellectual property. In more recent times, licensing is often the outcome of a successful period of collaboration on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the licensing agreement governs who has permission to commercialize and what payments are due should commercialization proceed. Other forms of licensing such as sub-licensing and cross-licensing are also explored, with examples provided together with listing of recent deals in pharma, biotech and diagnostics. The report provides a detailed understand and analysis of how and why companies enter licensing deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to commercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all licensing deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of licensing deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where collaborative R&D forms a part. Chapter 4 provides a review of the leading licensing deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a review of the top 50 most active biopharma companies in licensing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 6 provides a comprehensive review of licensing financials for deals announced since 2010, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials. Chapter 7 provides a comprehensive and detailed review of licensing deals signed and announced since 2010 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others. The report also includes numerous table and figures that illustrate the trends and activities in licensing deal making since 2010. In addition, a comprehensive appendix is provided organized by licensing company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In conclusion, this report provides everything a prospective dealmaker needs to know about licensing partnering in the research, development and commercialization of technologies and products. Key benefits Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010- 2017 provides the reader with the following key benefits: - In-depth understanding of licensing partnering deal trends since 2010 - Analysis of the structure of licensing agreements with numerous real life case studies - Comprehensive listing of over 4,500 licensing deals since 2010, together with deal terms, value and press release - Comprehensive access to actual licensing contracts entered into by the world's life science companies - Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates - Insight into the terms included in a licensing agreement, together with real world clause examples - Understand the key deal terms companies have agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010- 2017 is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide. Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010- 2017 includes: - Trends in licensing dealmaking in the biopharma industry since 2010 - Analysis of licensing deal structure - Case studies of real-life licensing deals - Comprehensive listing of over 4,500 licensing deals since 2010 - Access to licensing contract documents - Key financial bnchmarks for headline, upfront, milestone and royalty rates - The leading licensing deals by value since 2010 - Most active licensing dealmakers since 2010 - The leading licensing partnering resources In Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010- 2017 available deals and contracts are listed by: - Company A-Z - Headline value - Therapeutic area - Technology type Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand. The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010- 2017 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following: - What are the precise rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How do milestone align with clinical stage development phases? - How aresalesand payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - How is confidentiality and publication managed? - How are disputes to be resolved? - Under what conditions can the deal be terminated? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law? Download the full report: https://www.reportbuyer.com/product/4882433/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com   For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com   Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-licensing-partnering-terms--agreements-in-pharma-biotech--diagnostics-2010---2016-300451767.html


LONDON, May 4, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/3812931/ Description The Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides details of the latest distribution agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of distribution agreements from 2010 to 2017. The report provides a detailed understanding and analysis of how and why companies enter distribution deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of over 2,400 distribution deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners. The initial chapters of this report provide an orientation of distribution dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of distribution deals. The chapter includes numerous case studies to enable understanding of both pure distribution deals and multicomponent deals where distribution forms a part. Chapter 4 provides a review of the leading distribution deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a comprehensive listing of the top 50 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. Chapter 6 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2010 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal. The appendices to the report includes a comprehensive listing of all distribution deals announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document. The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2010. The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others. In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances. Key benefits Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides the reader with the following key benefits: - In-depth understanding of distribution deal trends since 2010 - Analysis of the structure of distribution agreements with numerous real life case studies - Comprehensive access to over 2,400 actual distribution deals entered into by the world's biopharma companies - Detailed access to actual distribution contracts entered into by leading biopharma companies - Identify the top most actve distribution dealmakers - Insight into the terms included in a distribution agreement, together with real world clause examples - Understand the key deal terms companies have agreed in previous deals - Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide. Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 includes: - Trends in distribution dealmaking in the biopharma industry since 2010 - Analysis of distribution deal structure - Case studies of real-life distribution deals - Access to over 2,400 distribution deals documents - The leading distribution deals by value since 2010 - Most active distribution dealmakers since 2010 - The leading distribution partnering resources In Distribution Partnering Terms and Agreements, the available deals are listed by: - - Company A-Z - Headline value - Stage of development at signing - Therapeutic area - Technology type Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available. The Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive access to available records for over 2,400 distribution deals, including contract documents where available. Analyzing actual contract agreements allows assessment of the following: - What are the precise rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How aresalesand payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - How is confidentiality and publication managed? - How are disputes to be resolved? - Under what conditions can the deal be terminated? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law? Download the full report: https://www.reportbuyer.com/product/3812931/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com   Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-distribution-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2010-to-2016-300451755.html

Loading Actavis collaborators
Loading Actavis collaborators